Evaluating [18F]3F4AP in Multiple Sclerosis and Healthy Volunteers
A study is currently evaluating the safety and pharmacokinetics of the PET tracer [18F]3F4AP in 60 healthy volunteers and subjects with multiple sclerosis. The study aims to assess binding in the brain over a follow-up period of 5 years. No results have been released yet as the study is still recruiting participants.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
This study is significant as it may provide insights into imaging techniques for demyelinating diseases, specifically multiple sclerosis, by evaluating a new tracer.
What this does not prove
The study has not yet reported results and is still in the recruitment phase, thus definitive findings are unknown.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 60 · Estimated
- Randomised
- No
- Controlled
- Yes
- Primary endpoint met
- Not reported
- Relevant MS type
- All
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Yes
- Research areas
- Not classified
Original sources
Supporting passages (15)
subjectsFirst evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions.
sample size"count": 60
sample size basis"type": "ESTIMATED"
randomized"allocation": "NON_RANDOMIZED"
controlled"type": "ACTIVE_COMPARATOR"
peer reviewed"pmid": "40759830"
regulatory approval"isFdaRegulatedDrug": true
regulatory approval details"isFdaRegulatedDrug": true
relevant ms typesFirst evaluation in multiple sclerosis using PET tracer [18F]3F4AP demonstrates heterogeneous binding across lesions.
intervention"name": "F-18 3F4AP"
comparator"type": "ACTIVE_COMPARATOR"
primary endpoint"measure": "Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects"
follow up"timeFrame": "5 years"
findings"briefSummary": "Our overall objective is to obtain an initial assessment of the potential value of using \\[18F\\]3F4AP for imaging demyelinating diseases such as multiple sclerosis:\n\n* Aim 1) Assess the safety of \\[18F\\]3F4AP in healthy volunteers and subjects with multiple sclerosis (MS).
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.